Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Omeros Corp announces investigational new drug application clearance by FDA for OMS721 in thrombotic microangiopathies


Thursday, 3 Apr 2014 07:00am EDT 

Omeros Corp:Says its Investigational New Drug Application to evaluate OMS721 for the inhibition of complement*mediated thrombotic microangiopathies has been cleared by the U.S. Food and Drug Administration (FDA). 

Company Quote

16.98
-1.01 -5.61%
4:00pm EDT